Collins John J, Devine Tom D, Dick Gina S, Johnson Elizabeth A, Kilham Henry A, Pinkerton C Ross, Stevens M M, Thaler Howard T, Portenoy Russell K
Pain and Palliative Care Service, The Children's Hospital at Westmead, Sydney, New South Wales 2145, Australia.
J Pain Symptom Manage. 2002 Jan;23(1):10-6. doi: 10.1016/s0885-3924(01)00375-x.
Few studies have attempted to describe the experience of symptoms in young children with cancer. This is due, in part, to the lack of validated symptom assessment scales for this patient population. The objective of this study was to evaluate the reliability and validity of a revised Memorial Symptom Assessment Scale (MSAS) in patients aged 7-12 as an instrument for the assessment of symptoms in young children with cancer. The MSAS (7-12) was administered to 149 children (inpatients and outpatients) who were undergoing treatment at either the Royal Marsden NHS Trust, London, United Kingdom or The Children's Hospital at Westmead, Sydney, Australia. Validity was evaluated by comparison with the medical record, parental report, and concurrent assessment on visual analogue scales for selected symptoms. The data provide evidence of the reliability and validity of MSAS (7-12) and demonstrate that children with cancer as young as 7 years can report clinically relevant and consistent information about their symptom experience. Young children with cancer experience multiple symptoms. Approximately one-third had experienced lethargy and/or pain and/or insomnia during the 48 hours prior to the completion of MSAS (7-12). The completion rate for MSAS (7-12) was high and the majority of children completed the instrument in a short period of time and with little difficulty. The instrument appears to be age appropriate and may be helpful to older children unable to independently complete MSAS (10-18). Systematic symptom assessment may be useful in future epidemiological studies of symptoms and in cancer chemotherapy drug trials.
很少有研究试图描述患癌幼儿的症状体验。部分原因在于缺乏针对该患者群体的经过验证的症状评估量表。本研究的目的是评估修订后的纪念症状评估量表（MSAS）在7至12岁患者中作为评估患癌幼儿症状工具的可靠性和有效性。MSAS（7 - 12）应用于149名儿童（住院患者和门诊患者），这些儿童在英国伦敦的皇家马斯登国民保健服务信托基金医院或澳大利亚悉尼的韦斯特米德儿童医院接受治疗。通过与病历、家长报告以及对选定症状的视觉模拟量表进行同步评估来评估有效性。数据提供了MSAS（7 - 12）可靠性和有效性的证据，并表明年仅7岁的患癌儿童能够报告与其症状体验相关且一致具有临床意义的信息。患癌幼儿会经历多种症状。在完成MSAS（7 - 12）之前的48小时内，约三分之一的儿童经历过嗜睡和/或疼痛和/或失眠。MSAS（7 - 12）的完成率很高，大多数儿童在短时间内且几乎没有困难地完成了该量表。该量表似乎适合相应年龄段，可能有助于无法独立完成MSAS（10 - 18）的大龄儿童。系统的症状评估可能在未来症状的流行病学研究和癌症化疗药物试验中有用。
